Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

Adrenal tumors provide insight into the role of cortisol in NK cell activity

Greenstein et al. • 2021 • Endocr Relat Cancer . 2021 Jun 29;28(8):583-592. doi: 10.1530/ERC-21-0048.

Hypercortisolism (Cushing syndrome)

Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search

Isaac Sachmechi, MD, FACE, FACP; Sanna Salam; Muhammad Umair, MD; Kathleen Wade Tarnowski, MSc • 2021 •

Hypercortisolism (Cushing syndrome)

Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis

Albert W. Coo, MD, FACE; Rebecca Ray, FNP-C • 2021 •

Suppression of Tumor Immune Activity in Adrenocortical Carcinoma with Excess Glucocorticoid

Greenstein et al. • 2020 • AACR Annual Meeting 2020

Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.

Greenstein et al. • 2020 • Citation: J Clin Oncol 38: 2020 (suppl; abstract #: 3091)

Hypercortisolism (Cushing syndrome)

GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

Auchus et al. • 2020 • J Endocr Soc. Vol 4, Issue Suppl 1 April-May

Hypercortisolism (Cushing syndrome)

Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients

Steffensen et al • 2019 • Horm Metab Res.

Hypercortisolism (Cushing syndrome)

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Pivonello et al • 2021 • Front. Endocrinol., 14 July 2021

Relacorilant With Nab-paclitaxel: Safety and Activity in Patients With Pancreatic Ductal Adenocarcinoma and Ovarian Cancer

Munster et al. • 2019 •

Hypercortisolism (Cushing syndrome)

Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator, Relacorilant (up to 400 mg/day), in Patients With Endogenous Hypercortisolism

Pivonello et al. • 2019 • American Association of Clinical Endocrinologists (AACE) 28th Annual Scientific & Clinical Congress